Influenza A Identified at 11 Sites in Four States in Wastewater Testing
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, Sept. 19, 2024 -- The findings from influenza A virus and H5 subtype monitoring of wastewater have been published in the Sep. 19 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Souci Louis, V.M.D., from the CDC in Atlanta, and colleagues present the results of monitoring influenza A virus levels and detection of the H5 subtype in wastewater as part of the response to the highly pathogenic avian influenza A(H5N1) virus outbreak in U.S. cattle and poultry and associated human cases.
A weekly average of 309 sites in 38 states had sufficient data for analysis among 48 states and the District of Columbia that performed influenza A testing of wastewater during May 12 to July 13, 2024. The researchers found that 11 of these sites in four states reported high levels of influenza A virus. H5 was detected at 24 sites in nine states after H5 subtype testing was conducted at 203 sites in 41 states. Three of the four states with high influenza A virus levels detected in wastewater had corresponding evidence of human influenza activity from other influenza surveillance systems. Fifteen of the 24 sites with H5 detections identified animal sources within the sewershed or adjacent county, including eight milk-processing inputs.
"The findings in this report, and data from wastewater surveillance in general, can complement traditional influenza surveillance systems," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-09-20 12:00
Read more
- Poor Cardiovascular Health Linked to Composite of Poor Brain Health
- Protracted Radiation Exposure Linked to Hematologic Cancer Mortality
- Geographic Position Influences Climate Change Risk Perception of Emergency Medical Services
- COVID-19 Linked to Long-Term Risk for Autoimmune, Autoinflammatory Disease
- ASN: Empagliflozin Offers Lasting Cardiorenal Benefit in CKD Patients
- Policies About Late-Career Physicians Are Considered Successful
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions